Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Analysis of gut and mucosal microbiomes in patients with extrahepatic cholangiocarcinoma.

Like many rare diseases, fibrolamellar hepatocellular carcinoma (FLC) mounts a ferocious attack against ... a senior researcher in the lab. “Ideally, our findings will refine the detection of the ...

Like many rare diseases, fibrolamellar hepatocellular carcinoma (FLC ... "Ideally, our findings will refine the detection of the disease, change the course of treatment, and increase patient ...

The study, published in Nature Communications, focused on AI-assisted radiotherapy for two types of cancer: non-small cell lung cancer and liver cancer (hepatocellular carcinoma). Radiotherapy is ...

Sonographic findings of quadriceps in child diagnosed with SMA: (A) Age 2 months: normal echogenicity and clearly visible internal septa. (B) Age 14 months, 6 months after onset of disease ...

Background/Aims: Transarterial chemoembolization (TACE) is widely performed as a major treatment for hepatocellular carcinoma (HCC ... further research is needed to prospectively validate our findings ...

MANILA, Philippines — The Department of Justice (DOJ) is reviewing the findings of the National Bureau of Investigation, which recently finished looking into the supposed threat made by Vice ...

Urothelial carcinoma (UC) of the upper urinary tract (UUT) is rare, constituting 5% to 10% of UCs, with a higher prevalence in males and older adults. It encompasses various subtypes and, unlike UC of ...